51
|
Chatel G, Ganeff C, Boussif N, Delacroix L, Briquet A, Nolens G, Winkler R. Hedgehog signaling pathway is inactive in colorectal cancer cell lines. Int J Cancer 2007; 121:2622-7. [PMID: 17683069 DOI: 10.1002/ijc.22998] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The Hedgehog (Hh) signaling pathway plays an important role in human development. Abnormal activation of this pathway has been observed in several types of human cancers, such as the upper gastro-intestinal tract cancers. However, activation of the Hh pathway in colorectal cancers is controversial. We analyzed the expression of the main key members of the Hh pathway in 7 colon cancer cell lines in order to discover whether the pathway is constitutively active in these cells. We estimated the expression of SHH, IHH, PTCH, SMO, GLI1, GLI2, GLI3, SUFU and HHIP genes by RT-PCR. Moreover, Hh ligand, Gli3 and Sufu protein levels were quantified by western blotting. None of the cell lines expressed the complete set of Hh pathway members. The ligands were absent from Colo320 and HCT116 cells, Smo from Colo205, HT29 and WiDr. GLI1 gene was not expressed in SW480 cells nor were GLI2/GLI3 in Colo205 or Caco-2 cells. Furthermore the repressive form of Gli3, characteristic of an inactive pathway, was detected in SW480 and Colo320 cells. Finally treatment of colon cancer cells with cyclopamine, a specific inhibitor of the Hh pathway, did not downregulate PTCH and GLI1 genes expression in the colorectal cells, whereas it did so in PANC1 control cells. Taken together, these results indicate that the aberrant activation of the Hh signaling pathway is not common in colorectal cancer cell lines.
Collapse
Affiliation(s)
- Guillaume Chatel
- Molecular Oncology Laboratory, Experimental Cancer Research Center, Center of Biomedical Integrative Genoproteomics, University of Liège, Liège, Belgium
| | | | | | | | | | | | | |
Collapse
|
52
|
Kobune M, Kato J, Kawano Y, Sasaki K, Uchida H, Takada K, Takahashi S, Takimoto R, Niitsu Y. Adenoviral vector-mediated transfer of the Indian hedgehog gene modulates lymphomyelopoiesis in vivo. Stem Cells 2007; 26:534-42. [PMID: 17962696 DOI: 10.1634/stemcells.2007-0741] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Indian hedgehog (Ihh) plays an essential role in angiogenesis, hematogenesis, and epiphysis formation during embryogenesis. In the present study, we injected an adenoviral vector (Adv) carrying the mock-control (Adv-control) or Ihh (Adv-Ihh) gene into severe combined immunodeficiency (SCID) or BALB/c mice to evaluate the effects of lhh on the regulation of postnatal hematopoiesis in vivo. After the i.v. injection of Adv-Ihh, the expression of vector-derived Ihh mRNA was detected in the liver. Four weeks after administration of Adv-Ihh to SCID mice, we observed an increase in the number of c-Kit+ cells and clonogenic cells per 10(5) mononuclear cells in the bone marrow compared with Adv-control-administered mice. Moreover, after administration of Adv-Ihh to BALB/c mice, the number of splenic B220+IgM(low)CD23(int)CD21(int) B lymphocytes and CD4+ T lymphocytes was strongly increased. Furthermore, the number of thymic double-negative (DN)2, DN3, CD8+ immature single-positive, and CD4+/CD8- cells was significantly elevated relative to the number in mice that received the control Adv vector. Our results suggest that enhanced signaling by Ihh can modulate the proliferation and differentiation of splenic B lymphocytes and thymic T lymphocytes during bone marrow hematopoiesis in vivo. Thus, modulation of the hedgehog signaling pathway may provide a therapeutic strategy to stimulate lymphomyelopoiesis in vivo.
Collapse
Affiliation(s)
- Masayoshi Kobune
- Fourth Department of Internal Medicine, Sapporo Medical University School of Medicine, Chuo-ku, South-1, West-16 Sapporo, Hokkaido 060-8556, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
53
|
Abstract
The sonic hedgehog (SHH) pathway was first defined genetically in fruit flies. Subsequently, the SHH network has been shown to be critical for normal mammalian development, by mediating interactions between stromal and epithelial cells. Recent evidence suggests that, deregulation of SHH signaling is important in the pathogenesis of cancer. Further, some observations suggest that a SHH paracrine mechanism mediating tumor-mesenchymal interactions may contribute to the metastatic capacity of cancer. Preclinical studies demonstrate that tumor cells in which SHH is deregulated are dependent on signaling through this pathway for the maintenance of proliferation and viability. SHH antagonists have been identified and show promise in inhibiting tumor growth in preclinical studies. The utility of these agents in the management of cancer patients awaits the outcome of ongoing and future clinical trials.
Collapse
Affiliation(s)
- Nikhil S Chari
- Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
| | | |
Collapse
|
54
|
Abstract
The Hedgehog pathway is critical for many developmental processes, including the formation of several epidermal appendages. In the mammary gland strict regulation of the Hedgehog pathway is required for normal development. Alterations in Hedgehog signaling result in defects in both the embryonic and postnatal mammary gland. Activation of Hedgehog signaling either by mutation or misexpression of pathway members can lead to the development and/or progression of cancers in multiple organs. This review addresses the current understanding and controversies of Hedgehog signaling in mammary gland development and its potential role in promoting breast carcinogenesis and cancer progression.
Collapse
Affiliation(s)
- Sarah Hatsell
- Department of Cell Biology, New York University School of Medicine, New York, NY 10016, USA
| | | |
Collapse
|
55
|
Yeh JJ, Der CJ. Targeting signal transduction in pancreatic cancer treatment. Expert Opin Ther Targets 2007; 11:673-94. [PMID: 17465725 DOI: 10.1517/14728222.11.5.673] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
Pancreatic cancer is a lethal disease with a 5-year survival rate of 4%. The only opportunity for improved survival continues to be complete surgical resection for those with localized disease. Although chemotherapeutic options are limited for the few patients with resectable disease, this problem is even more magnified in the majority (85%) of patients with unresectable or metastastic disease. Therefore, there is an urgent need for improved therapeutic options. The recent success of inhibitors of signal transduction for the treatment of other cancers supports the need to identify and validate aberrant signaling pathways important for pancreatic tumor growth. This review focuses on the validation of specific signaling networks and the present status of inhibitors of these pathways as therapeutic approaches for pancreatic cancer treatment.
Collapse
Affiliation(s)
- Jen Jen Yeh
- University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Division of Surgical Oncology, Chapel Hill, NC 27599, USA.
| | | |
Collapse
|
56
|
Abstract
Signaling pathways responsible for embryogenesis play a critical role in the maintenance of stem cells in adult life and cellular responses to injury. Dysfunction of the developmental signaling pathways during adult homeostasis leads to various events resulting in the development of neoplasia. We review the biology of the hedgehog signaling pathway and its potential role in the development of lung cancer.
Collapse
Affiliation(s)
- Vamsidhar Velcheti
- Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA
| | | |
Collapse
|
57
|
Peacock CD, Wang Q, Gesell GS, Corcoran-Schwartz IM, Jones E, Kim J, Devereux WL, Rhodes JT, Huff CA, Beachy PA, Watkins DN, Matsui W. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci U S A 2007; 104:4048-53. [PMID: 17360475 PMCID: PMC1805487 DOI: 10.1073/pnas.0611682104] [Citation(s) in RCA: 341] [Impact Index Per Article: 20.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
The cancer stem cell hypothesis suggests that malignant growth depends on a subset of tumor cells with stem cell-like properties of self-renewal. Because hedgehog (Hh) signaling regulates progenitor cell fate in normal development and homeostasis, aberrant pathway activation might be involved in the maintenance of such a population in cancer. Indeed, mutational activation of the Hh pathway is associated with medulloblastoma and basal cell carcinoma; pathway activity is also critical for growth of other tumors lacking such mutations, although the mechanism of pathway activation is poorly understood. Here we study the role and mechanism of Hh pathway activation in multiple myeloma (MM), a malignancy with a well defined stem cell compartment. In this model, rare malignant progenitors capable of clonal expansion resemble B cells, whereas the much larger tumor cell population manifests a differentiated plasma cell phenotype that pathologically defines the disease. We show that the subset of MM cells that manifests Hh pathway activity is markedly concentrated within the tumor stem cell compartment. The Hh ligand promotes expansion of MM stem cells without differentiation, whereas the Hh pathway blockade, while having little or no effect on malignant plasma cell growth, markedly inhibits clonal expansion accompanied by terminal differentiation of purified MM stem cells. These data reveal that Hh pathway activation is heterogeneous across the spectrum of MM tumor stem cells and their more differentiated progeny. The potential existence of similar relationships in other adult cancers may have important biologic and clinical implications for the study of aberrant Hh signaling.
Collapse
Affiliation(s)
| | - Qiuju Wang
- *Sidney Kimmel Comprehensive Cancer Center and
| | | | | | - Evan Jones
- *Sidney Kimmel Comprehensive Cancer Center and
| | - Jynho Kim
- Department of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, MD 21231; and
- Department of Developmental Biology, Institute for Stem Cell Biology and Regenerative Medicine, Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA 94305
| | | | | | | | - Philip A. Beachy
- Department of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, MD 21231; and
- Department of Developmental Biology, Institute for Stem Cell Biology and Regenerative Medicine, Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA 94305
- To whom correspondence may be addressed. E-mail:
, , or
| | - D. Neil Watkins
- *Sidney Kimmel Comprehensive Cancer Center and
- To whom correspondence may be addressed. E-mail:
, , or
| | - William Matsui
- *Sidney Kimmel Comprehensive Cancer Center and
- To whom correspondence may be addressed. E-mail:
, , or
| |
Collapse
|
58
|
Sato N, Goggins M. The role of epigenetic alterations in pancreatic cancer. ACTA ACUST UNITED AC 2007; 13:286-95. [PMID: 16858539 DOI: 10.1007/s00534-005-1057-1] [Citation(s) in RCA: 53] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2005] [Accepted: 09/01/2005] [Indexed: 12/22/2022]
Abstract
The past several years have witnessed an explosive increase in our knowledge about epigenetic features in human cancers. It has become apparent that pancreatic cancer is an epigenetic disease, as it is a genetic disease, characterized by widespread and profound alterations in DNA methylation. The introduction of genome-wide screening techniques has accelerated the discovery of a growing list of genes with abnormal methylation patterns in pancreatic cancer, and some of these epigenetic events play a role in the neoplastic process. The detection and quantification of DNA methylation alterations in pancreatic juice is likely a promising tool for the diagnosis of pancreatic cancer. The potential reversibility of epigenetic changes in genes involved in tumor progression makes them attractive therapeutic targets, but the efficacy of epigenetic therapies in pancreatic cancer, such as the use of DNA methylation inhibitors, remains undetermined. In this review, we briefly summarize recent research findings in the field of pancreatic cancer epigenetics and discuss their biological and clinical implications.
Collapse
Affiliation(s)
- Norihiro Sato
- Department of Pathology, The Johns Hopkins Medical Institutions, The Sol Goldman Center for Pancreatic Cancer Research, 342 Cancer Research Building 2, 1550 Orleans St., Baltimore, MD 21231, USA
| | | |
Collapse
|
59
|
Abstract
Pancreatic ductal adenocarcinoma is one of the most aggressive human malignancies, with an overall 5-year survival rate of less than 4%. On the molecular level, an increasing number of genetic and epigenetic alterations have been discovered, with a particular focus on growth factors and related pathways. Small-molecule tyrosine kinase inhibitors, antibodies, and other approaches have been developed in recent years to target these signal transduction pathways, and first clinical trials show encouraging results. In addition, molecular alterations have been identified that enable the cancer cells to invade the perineurium and the retroperitoneal space, thus explaining at least in part the high rate of local recurrence and the severe pain syndrome. Technically, pancreatic surgery has advanced, with acceptable morbidity and mortality rates in high-volume centers. Randomized controlled trials are increasingly carried out to define the best palliative and adjuvant therapy for this disease. Translational research combined with clinical trials will hopefully lead to improved survival and better quality of life for pancreatic cancer patients in the future.
Collapse
Affiliation(s)
- Jörg Kleeff
- Department of General Surgery, University of Heidelberg, Heidelberg, Germany
| | | | | | | |
Collapse
|
60
|
Bu XM, Zhao CH, Zhang N, Wang W, Li Y, Dai XW. Role of multiple genes methylation in pancreatic carcinogenesis. Shijie Huaren Xiaohua Zazhi 2006; 14:1416-1419. [DOI: 10.11569/wcjd.v14.i14.1416] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To determine methylation status of RASSF1A, p16, SOCS-1 and hMLH1 genes and explore the roles of their concurrent methylation in the carcinogenesis of pancreatic cancer.
METHODS: DNA in pancreatic cancer and cancer-adjacent tissues was extracted by saturated NaCl method. The methylation status of these genes was detected by methylation-specific polymerase chain reaction (MSP).
RESULTS: The methylation rates of RASSF1A, p16, SOCS-1 and hMLH1 were 36.4%, 13.6%, 13.6% and 4.5% in cancer-adjacent tissues and 59.1%, 40.9%, 31.8% and 18.2% in pancreatic cancer, respectively. The methylation rate of p16 in pancreatic cancer was significantly higher than that in the cancer-adjacent tissues (χ2 = 4.13, P < 0.05). Two or more genes concurrent methylation was found in 45.5% pancreatic cancer, significantly higher than that in the cancer-adjacent tissues (9.1%, χ2 = 7.33, P < 0.01). No methylation of these genes was found in 31.8% pancreatic cancer.
CONCLUSION: Multiple genes concurrent methylation is an early event in some cases of pancreatic cancer, in which it plays an important role.
Collapse
|
61
|
Speek M, Njunkova O, Pata I, Valdre E, Kogerman P. A potential role of alternative splicing in the regulation of the transcriptional activity of human GLI2 in gonadal tissues. BMC Mol Biol 2006; 7:13. [PMID: 16553965 PMCID: PMC1435915 DOI: 10.1186/1471-2199-7-13] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2005] [Accepted: 03/23/2006] [Indexed: 01/15/2023] Open
Abstract
BACKGROUND Mammalian Gli proteins are important transcription factors involved in the regulation of Sonic hedgehog signal transduction pathway. Association of Gli2 with mammalian development and human disease led us to study the structure and expression of the human GLI2. RESULTS We show that the region encoding GLI2 repressor domain is subject to alternative splicing in the gonadal tissues and different cell lines. Two major alternatively spliced forms of GLI2 mRNA arise from skipping exon 3 (GLI2Delta3) or exons 4 and 5 (GLI2Delta4-5). Both forms contain premature translational stop codons in the GLI2 open reading frame (ORF) starting from exon 2. Translation of GLI2Delta3 and GLI2Delta4-5 in vitro, initiated from downstream AUG codons, produced N-terminally truncated proteins. In Gli-dependent transactivation assay, expression of GLI2Delta3 induced activation of the reporter gene similar to that of the full-length construct (GLI2fl) containing complete ORF. However, expression of the GLI2Delta4-5 resulted in about 10-fold increase in activation, suggesting that deletion of the major part of repressor domain was responsible for the enhanced activation of GLI2 protein. CONCLUSION Our data suggest that in addition to proteolytic processing, alternative splicing may be another important regulatory mechanism for the modulation of repressor and activator properties of GLI2 protein.
Collapse
Affiliation(s)
- Mart Speek
- Department of Gene Technology, Tallinn University of Technology, Akadeemia tee 15, 19086 Tallinn, Estonia
| | - Olga Njunkova
- Department of Gene Technology, Tallinn University of Technology, Akadeemia tee 15, 19086 Tallinn, Estonia
- Department of Molecular Genetics, National Institute for Chemical Physics and Biophysics, Akadeemia tee 23, 12618 Tallinn, Estonia
| | - Illar Pata
- Department of Gene Technology, Tallinn University of Technology, Akadeemia tee 15, 19086 Tallinn, Estonia
- Department of Molecular Genetics, National Institute for Chemical Physics and Biophysics, Akadeemia tee 23, 12618 Tallinn, Estonia
| | - Eola Valdre
- Department of Molecular Genetics, National Institute for Chemical Physics and Biophysics, Akadeemia tee 23, 12618 Tallinn, Estonia
- Diagnostic Clinic, East-Tallinn Central Hospital, Ravi 18, 10138 Tallinn, Estonia
| | - Priit Kogerman
- Department of Gene Technology, Tallinn University of Technology, Akadeemia tee 15, 19086 Tallinn, Estonia
- Department of Molecular Genetics, National Institute for Chemical Physics and Biophysics, Akadeemia tee 23, 12618 Tallinn, Estonia
| |
Collapse
|